Dosage Form
- Oral tablets: 10 mg and 20 mg
- Packaging: Boxes of 30 tablets
Indications
- Chronic Kidney Disease (CKD) in patients with Type 2 diabetes mellitus
- Heart failure with preserved or mildly reduced ejection fraction
- LVEF ≥ 40%
- One of the limited therapeutic options for HFpEF (LVEF ≥ 50%)
Clinical Benefits of Kinerin
- Significant reduction in albuminuria in patients with diabetic CKD
- Slowing the decline of glomerular filtration rate (GFR)
- Reduction in heart-failure–related hospitalizations and cardiovascular mortality
- High selectivity for the mineralocorticoid receptor
- Improved safety profile and better tolerability compared with steroidal MRAs
Mechanism of Action
Kinerin inhibits the effects of aldosterone, leading to:
- Reduction of inflammation and fibrosis in the kidney and heart
- Improvement of endothelial function
- Increased urinary excretion of sodium and water
Target Dose and Administration
Chronic Kidney Disease in Patients with Diabetes
Heart Failure
- eGFR ≥ 60 mL/min/1.73 m²:
- eGFR 25–60 mL/min/1.73 m²:
Missed Dose
- If a dose is missed, it should be taken as soon as remembered on the same day
- If an entire day has passed, the missed dose should be skipped and the next dose taken as scheduled
Warnings and Precautions
- Serum potassium levels should be monitored every 4 weeks due to the risk of hyperkalemia
- Closer monitoring is required in patients with impaired renal function
Contraindications
- Serum potassium > 5.0 mEq/L
- eGFR < 25 mL/min/1.73 m²
- Pregnancy and breastfeeding (animal studies suggest potential fetal harm)
Drug Interactions
- Concomitant use with strong CYP3A4 inhibitors is contraindicated
- Patients should inform their physician of all concomitant medications
Storage Conditions
- Store at temperatures below 30°C
- Protect from light and moisture
- Keep in the original packaging
- Do not use after the expiration date printed on the package
